Keeping an eye on Communist, Totalitarian China, and its influence both globally, and we as Canadians. I have come to the opinion that we are rarely privy to truth regarding the real goal, the agenda of Red China, and it's implications for Canada [and North America as a whole]. No more can we rely on our media as more and more information on China is actively being swept under the carpet - not for consumption.
Sunday, February 2, 2020
WuXi AppTec.. a Globalist Pharmaceutical Company: Chinese Virus Researchers and Designers
Established in December 2000, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 3,700 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated".
SHANGHAI, Aug. 22, 2018 /PRNewswire/ -- WuXi AppTec (603259.SH), a leading global pharmaceutical and medical device open-access capability and technology platform company, today announces the appointment of Mr. Edward Hu as Co-CEO of the company. Mr. Hu will continue to report to Dr. Ge Li, Chairman and CEO of WuXi AppTec.
As the company's Co-CEO, Mr. Hu will share business management responsibilities with Dr. Li, including the small molecule drug discovery, development, manufacturing services, drug and medical device testing services, etc. Mr. Hu will continue to act as the CFO in charge of corporate finance, investment, and mergers and acquisitions, until a new CFO comes on board.
Since joining WuXi in 2007, Mr. Hu has served as the company's Chief Operating Officer, and later Chief Financial Officer and Chief Investment Officer. Over the past decade, he has scored significant achievements in operational excellence, financial management, and WuXi's global business expansion. Mr. Hu was elected to the Board of Directors in March 2016.
"Ed's extraordinary business leadership has been, and will continue to be critical to the growth of WuXi AppTec," stated Dr. Ge Li, Chairman and CEO of WuXi AppTec. "I look forward to working closely with Ed as we enter an exciting new era of growth, and please join me in wishing him even greater success in his new role."
"I'm very grateful for the trust placed in me by the board and Dr. Li," said Mr. Hu. "It's our vision to enable anyone and any company to realize their R&D dream, so that patients can benefit from earlier access to better medicines. Together, we will strive to fulfill WuXi's dream that every drug can be made and every disease can be treated."
Prior to WuXi, Mr. Hu served as Senior Vice President and Chief Operating Officer at Tanox.
His earlier career spanned managerial and financial positions at Biogen and Merck respectively. Mr. Hu has an MBA and Master's degree in Chemistry from Carnegie Mellon University.
About WuXi AppTec
WuXi AppTec is a leading pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our customers and partners worldwide shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, the WuXi platform is enabling nearly 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Please visit: https://www.wuxiapptec.com
Dr Ge Li, Founder, Chairman and CEO of WuXi AppTec was awarded ‘CEO of the Year’ for his significant contribution to the global biopharma R&D industry
Cambrex was awarded ‘API Development’ for the second time in three years for its Crystallisation Screening and Process Development Service
John Chiminski, Chair and CEO at Catalent Pharma Solutions, won the ‘Lifetime Achievement’ award for his accomplishments spanning more than three decades
Nanoform was given the ‘Formulation’ award for its controlled expansion of supercritical solutions (CESS®)
Spraying Systems Co/Fluid Air Inc was given the ‘Manufacturing Technology and Equipment’ award for its PolarDry® – the Cooler Technology
Univercells received the ‘Bioprocessing and Manufacturing’ awardin recognition of its NevoLine PlatformTM, which is a bioproduction system for vaccines
Merck Healthcare KGaA was awarded the ‘Regulatory Procedures and Compliance’ prize for ‘Project SARA’ (Smart Assistant for Regulatory Affairs)
MedPharm won the ‘Analysis, Testing, and Quality Control’ category for pioneering the regulatory approval of topical products using in vitro bioequivalence
SCHOTT Pharmaceutical Systems and W L Gore & Associates received the ‘Packaging’ award for their syriQ BioPure® – a silicone-free syringe – whilst Hoffmann Neopac was highly commended for its STYLO Spatula applicator
Lonza Pharma & Biotech was the winner of the ‘Pharma Service Company of the Year Award’ for its integrated global services offering that spans the pharmaceutical, biotech, consumer health and specialty chemicals market
Nanopharm Ltd was selected as the winner of the ‘Contract Services and Outsourcing’ award for SmartTrack™, with CMAC being highly commended for its CMAC National Facility
Phillips-Medisize was given the award for ‘Drug Delivery and Devices’ for its Connected Health Platform
Kemiex AG won the ‘Supply Chain, Logistics and Distribution’ category.
“The judges noted that this year our entries possessed an extremely high standard,” said Tara Dougal, Head of Content at Informa. “All of the finalists would have would have made outstanding winners in previous years. On behalf of CPhI Worldwide, I would like to extend my congratulations to all the winners and commend all of the finalists.
“What you are doing is of tremendous benefit to the industry, but more importantly, it is also directly contributing to improved patient experiences globally.”
Ge Li, Ph.D.
Chairman and CEO
Scientist and entrepreneur leading WuXi since its founding in 2000. Ph.D. in Organic Chemistry from Columbia University. Awards and honors include "2018 SAPA Distinguished Achievement Award", "2018 The 40 Most Influential People in Pharmaceutical Industry in Commemoration of the 40th Anniversary of Reform and Opening-up", "2016 CBA Brilliant Achievement Award", "2015 SCRIP Executive of the Year Award", "2015 The 25 Most Influential People in Biopharma", "2009 The 60 Most Influential People during 60 Years Pharmaceutical Development in China", "2008 Forbes 25 Notable Chinese-Americans", and "2007 Ernst & Young Entrepreneur of the Year China".
Co-CEO at WuXi AppTec. With experience in operational excellence, financial management and global business expansion, Mr. Hu has demonstrated his extraordinary leadership to help the business expand further. Prior to WuXi, Mr. Hu served as Senior Vice President and Chief Operating Officer at Tanox. His earlier career spanned managerial and financial positions at Biogen and Merck respectively. Mr. Hu has an MBA and Master's degree in Chemistry from Carnegie Mellon University.
Steve Yang, Ph.D.
Executive Vice President, Chief Business Officer, Head of RSD, Head of LTD
Formerly Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, Vice President, Head of R&D Asia at Pfizer. Ph.D. in Pharmaceutical Chemistry from University of California, San Francisco.
Minzhang Chen, Ph.D.
Executive Vice President, CEO of STA
Over 20 years' experience in pharmaceutical development and manufacturing. Played important roles in R&D and commercialization of multiple innovative drugs for global launches. The Medicine Maker's 2019 Power List - one of the industry's most prominent 'Business Captains'. Formerly Director of Technical Operations at Vertex. B.S. in Chemistry from Peking University and Ph.D. in Organic Chemistry from University of Minnesota.
Executive Vice President, Head of the Strategic Project Office
One of our founders, entrepreneur. B.S. from Peking University and EMBA from China Europe International Business School.
Shuhui Chen, Ph.D.
Executive Vice President, Chief Scientific Officer, Head of DDSU
Over 29 years' experience in medicinal chemistry, formerly Research Advisor at Eli Lilly, Vion Pharmaceuticals and Bristol-Myers Squibb. Joined WuXi AppTec in 2004 as Chief Scientific Officer. Ph.D. in Organic Chemistry from Yale University.
Senior Vice President, Head of Government Affairs and Policy Research
One of our founders, entrepreneur, formerly Vice President of Domestic Marketing of WuXi AppTec. EMBA from China Europe International Business School.
Ning Zhao, Ph.D.
Senior Vice President, Global Head of Human Resources
One of our co-founders, formerly Vice President of Analytical Services and Lead Advisor of Analytical Services Operations of WuXi AppTec, previously held various positions at Bristol-Myers Squibb, Pharmacopeia, and Wyeth. Ph.D. in Organic Chemistry from Columbia University.
Senior Vice President, Chief Financial Officer
Formerly Managing Director and senior M&A banker at Citigroup and Merrill Lynch, Mr. Chu led the execution on many of the most strategic and transformative cross-border deals. B.S. in Electrical Engineering from Northwestern University and MBA from Columbia Business School.
Senior Vice President, Chief Operating Officer
Almost 20 years of experiences and expertise in business, operations and HR management in Huawei. Held progressive positions as Assistant President of Huawei University, Consumer Business Group (CBG) South Pacific Region President, HRVP of CBG, VP of Huawei Group HR department etc. Master and bachelor degrees in legal major from Wuhan University.
Jerry Chen, Ph.D.
Senior Vice President, Chief Digital Officer
Dr. Chen has profound experience in leading strategic designs and practical applications in healthcare big data and Artificial Intelligence. He founded Tencent Medical Big Data Lab, and Alibaba Health's Big Data and AI team. Formerly a tech lead of the Cards team at Twitter in San Francisco. Ph.D. in Computer Science and Engineering from University of Michigan.
Richard Connell, Ph.D.
Senior Vice President, US Chief Operating Officer
Over 27 years of experience in the biotech and drug discovery sector, most recently as Vice President of External Research Solutions at Pfizer. Managed a global network of Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), Biotech, technology and academic partnerships. Held multiple management positions in the US, UK, Germany and China while at Pfizer and Bayer. Ph.D. in Organic Chemistry from University of Notre Dame.
Jingchao Dong, Ph.D.
Senior Vice President, Head of CSU
One of the founding scientists of the company. Formerly Vice President of International Discovery Service Unit, responsible for the management of Shanghai, Wuhan and Tianjin site. Ph.D. in medicinal chemistry from Peking University.
Xiaoyong Fu, Ph.D.
Senior Vice President, Head of STA API Business
Over 27 years' experience in Organic Chemistry, small molecule API process R&D and Manufacturing, Process technology transfer as well as overall CMC. Formerly Sr. Fellow of Process Chemistry at Schering-Plough/MSD. Ph.D. in Organic Chemistry from University of Wisconsin-Milwaukee.
Fred Hausheer, M.D., FACP
Senior Vice President, Global Chief Medical Officer
Rich experience in global preclinical and Phase I-III oncology drug development, translational science and medicine in commercial and academic settings. Formerly CEO and CMO of several Biopharma companies, the Founder and Chairman of BioNumerik Pharmaceuticals, served as a business advisory board member to JP Morgan Chase, the Whittaker Institute at Johns Hopkins, and the National Cancer Institute. M.D. from the University of Missouri, School of Medicine, and Medical Oncology fellowship at Johns Hopkins.
Senior Vice President, Head of the Advanced Therapy Unit
Over 14 years' experience at Medtronic for MDT Cardiac Surgery and MDT Corporate based in Minneapolis and Hong Kong. Key positions included GM for Cardiac Surgery in Asia Pacific and VP of Global Supply Chain. MBA from University of Michigan and B.S. in Electrical Engineering from General Motors Institute.
Wei Zhang, M.D., Ph.D.
Senior Vice President, Chief Strategy Officer
Formerly faculty of Peking University and China Europe International Business School (CEIBS), and founding director of Health Care Management and Policy Center at CEIBS. Co-founded multiple start-ups across different sectors. Responsible for company strategy management. M.D. from Peking Union Medical College, and Ph.D. in Health Policy from Harvard University.